Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis.[4][5][6] It binds to the protein interleukin (IL)-17A and is marketed by Novartis.[4][5][6]
^"Cosentyx (Novartis Pharmaceuticals Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 7 October 2022. Retrieved 9 April 2023.
^"Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
^"Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
^ abc"Cosentyx 150mg and 300mg solution for injection in pre-filled syringe and pre-filled pen - Summary of Product Characteristics (SmPC)". (emc). 6 June 2022. Retrieved 9 November 2022.
^ abc"Cosentyx- secukinumab injection". DailyMed. 4 November 2022. Retrieved 9 November 2022.
^ abcCite error: The named reference Cosentyx EPAR was invoked but never defined (see the help page).
Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis...
demonstrated that bimekizumab is superior to not only adalimumab but also secukinumab and ustekinumab for the treatment of plaque psoriasis. "Bimzelx APMDS"...
well as the IL-12/IL-23 inhibitor ustekinumab, the IL-17A inhibitor secukinumab, and the IL-23 inhibitor risankizumab. Biologics may increase the risk...
Woessner, Ralph; Pieber, Thomas Rudolf; Cheng, Yi (November 23, 2015). "Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated...
this class target IL-17, an important part of the inflammatory system: secukinumab and ixekizumab. They are often considered in cases where TNFi drugs are...
changes. In May 2023, the European Commission (EC) approved Cosentyx (secukinumab) for active moderate to severe hidradenitis suppurativa in adults. Other...
severe cases of psoriasis. There is also some evidence to support use of secukinumab, brodalumab, guselkumab, certolizumab, and ustekinumab. In general, anti-IL17...
antibodies available or studied as injector pens include adalimumab, secukinumab, and alirocumab. CGRP antagonists which are monoclonal antibodies, used...
Global Information
(what is this?) (verify)